THE CHROMOSOME | Clinical Content Series
Pituitary Microadenomas
Back to Case Studies ArchiveCase Study
She was 33 years old and had been gaining weight for three years without being able to explain why, not to herself and not to the four physicians she had consulted in that time. She was eating the same food she had always eaten, living the same life she had always lived, exercising with the same moderate consistency she had maintained through her late twenties. And yet 21 kilograms had arrived across those three years with a steadiness that felt biological rather than behavioural, as though her body had made a decision she had not been consulted about and was executing it regardless of what she chose to eat or how she chose to move.
She had irregular periods, arriving every six to eight weeks when previously they had been reliably monthly. She had galactorrhoea, the milky breast discharge that she had been too embarrassed to mention to anyone until it had become impossible to ignore and she had finally disclosed it, with visible discomfort, to her gynaecologist eighteen months earlier. Her gynaecologist had ordered a prolactin level, found it elevated at 87 nanograms per millilitre against an upper normal of 25, and referred her to an endocrinologist. The endocrinologist had confirmed the hyperprolactinaemia and prescribed cabergoline, a dopamine agonist medication that suppresses prolactin, without ordering an MRI of her pituitary. The prolactin had fallen on medication. She had been told she was managed.
She came to me not because the medication was not working, it was controlling her prolactin numerically. She came because the weight was not resolving. Eighteen months of cabergoline, with prolactin numbers that her endocrinologist was satisfied with, had produced no meaningful change in the 21 kilograms she had arrived with. The medication had addressed the prolactin elevation. Nobody had addressed the pituitary lesion potentially producing it, the metabolic consequences of eighteen months of hyperprolactinaemia before treatment, or the broader hormonal disruption that a pituitary microadenoma creates beyond its prolactin output.
When I evaluated her comprehensively and insisted on an MRI of the pituitary, which should have been the first investigation ordered when her elevated prolactin was identified eighteen months earlier, a 6 millimetre prolactinoma was identified in the left side of the pituitary gland. Small enough to have been missed on a less detailed scan. Large enough to have been altering her hormonal environment for years before her galactorrhoea made the prolactin elevation unmistakable enough to investigate.
I want to expand the clinical scope of this case study beyond prolactinomas, because pituitary microadenomas are not exclusively prolactin secreting, and the range of hormonal disruptions they produce in Pakistani patients is substantially broader than the prolactin focused presentation that most commonly triggers investigation. Pituitary microadenomas, defined as pituitary tumours smaller than 10 millimetres, can secrete prolactin, growth hormone, ACTH, TSH, LH, or FSH in excess, or they can be non-functioning, producing no excess hormone themselves but disrupting the normal pituitary output of surrounding tissue through compression and local inflammatory effects. Each secretory type produces a distinct hormonal syndrome. Each non-functioning adenoma produces a distinct pattern of pituitary insufficiency through the hormonal axes it compresses. And all of them produce weight gain, metabolic deterioration, and hormonal disruption that is driven from the apex of the endocrine hierarchy, the pituitary gland that governs every hormonal axis below it.
The clinical importance of pituitary microadenomas in Pakistani obesity medicine lies in their consistent underdiagnosis, because pituitary MRI is expensive, not universally available, and not ordered unless a physician specifically considers a pituitary origin for the hormonal disruption they are evaluating. Pakistani physicians who do not consider pituitary pathology as a differential diagnosis in their obesity and hormonal assessments, which is the majority, will never identify a pituitary microadenoma regardless of how obvious its hormonal consequences become. The patient will be treated for the hyperprolactinaemia, or the Cushing's features, or the growth hormone excess, or the pituitary insufficiency, without the imaging that would identify the structural origin of the hormonal disruption and allow treatment to be directed at its source.
Her metabolic assessment revealed the full picture of what eighteen months of unaddressed prolactinoma had produced in a woman with the FTO associated metabolic predisposition. Her fasting insulin was significantly elevated, driven by the direct insulin resistance promoting effects of hyperprolactinaemia and the dopamine pathway disruption that elevated prolactin produces in the hypothalamic metabolic regulation centres. Her SHBG was critically suppressed, amplifying the biological activity of her androgens through the SHBG mediated free hormone mechanism I described in Disorder 27. Her oestrogen was suppressed, the GnRH inhibition driven by hyperprolactinaemia had reduced her ovarian oestrogen output, removing the metabolic protection that oestrogen provides against visceral fat accumulation in premenopausal women. Her growth hormone axis was impaired, because the prolactinoma had created a local compressive and inflammatory pituitary environment that was impacting the growth hormone secreting somatotroph cells adjacent to the prolactin secreting lactotroph cells housing the adenoma. Her cortisol pattern was dysregulated. Her vitamin D was profoundly deficient.
The FTO gene's relationship with pituitary microadenoma development in Pakistani patients is not a direct genetic predisposition to pituitary tumour formation, pituitary adenomas arise from somatic mutations in pituitary cells rather than from inherited germline genetic variants in the majority of cases. The FTO connection is metabolic and indirect, the FTO associated chronic inflammatory environment, insulin resistance, and dopaminergic pathway disruption that visceral obesity produces may create a pituitary cellular environment that is less resistant to the somatic mutations that produce adenoma formation and more vulnerable to the growth promoting signals that sustain adenoma development once initiated. More directly relevant is the FTO associated metabolic amplification of the hormonal consequences that pituitary microadenomas produce, because the same degree of prolactin elevation, or growth hormone excess, or ACTH overproduction produces more severe and more rapidly progressive metabolic consequences in a Pakistani patient carrying the FTO associated predisposition than in a metabolically normal patient with the same pituitary lesion.
We did not simply continue the cabergoline that had been normalising her prolactin numerically. We addressed the full metabolic and hormonal picture that eighteen months of prolactinoma had produced. We optimised her cabergoline dosing to achieve not merely prolactin normalisation but dopaminergic restoration at the hypothalamic level, because the dopamine pathway disruption of hyperprolactinaemia produces metabolic consequences that persist beyond prolactin normalisation if dopaminergic tone is not fully restored. We treated her insulin resistance, removing the metabolic driver that hyperprolactinaemia had established and that prolactin normalisation alone had not reversed. We restored her oestrogen, addressing the visceral fat accumulation and metabolic protection deficit that GnRH suppression had produced. We recalibrated her cortisol. We supported her growth hormone axis, addressing the pituitary compression effect on adjacent somatotroph function. We optimised her vitamin D.
Thirteen months later she had lost 17 kilograms. Her prolactin was well controlled on optimised cabergoline. Her insulin resistance had resolved. Her oestrogen had normalised. Her periods had returned to a regular monthly cycle. Her galactorrhoea had completely resolved. Her growth hormone axis had partially recovered as the compressive pituitary environment improved with adenoma response to dopamine agonist treatment. Her repeat MRI showed adenoma reduction from 6 millimetres to 3 millimetres, a response consistent with the expected cabergoline induced prolactinoma shrinkage that confirms both the diagnosis and the treatment response.
She had been managed for eighteen months. She had been treated for thirteen. The difference between those two states was the difference between controlling a number and addressing a patient, and in Pakistani pituitary medicine, the distinction between those two approaches is rarely made.
FAQs
A pituitary microadenoma is a benign tumour of the pituitary gland measuring less than 10 millimetres, small enough to be invisible on non dedicated imaging but large enough to significantly alter the hormonal output of the gland that governs every endocrine axis in the body. Its relevance to obesity in Pakistani patients lies in its position at the apex of the hormonal hierarchy, a microadenoma that alters prolactin, growth hormone, ACTH, or the gonadotropin output of the pituitary gland creates downstream hormonal disruptions across every axis that pituitary hormone governs, producing weight gain, metabolic deterioration, and hormonal disorder that is driven from the highest level of the endocrine system and that no treatment directed at the downstream consequences can adequately resolve without addressing the pituitary origin. In Pakistani obesity medicine, pituitary pathology is almost never considered, because pituitary MRI is not ordered unless a physician thinks to request it, and Pakistani physicians rarely think to request it.
Prolactinomas, the most common pituitary microadenoma, drive weight gain through hyperprolactinaemia's direct insulin resistance promoting effects, its suppression of GnRH and consequent oestrogen reduction, its dopaminergic disruption of hypothalamic metabolic regulation, and its direct adipogenic effects on visceral fat accumulation. Corticotroph microadenomas, producing excess ACTH and consequently excess cortisol, drive the central visceral obesity, insulin resistance, and muscle wasting of Cushing's disease in its subclinical or frank form. Somatotroph microadenomas, producing excess growth hormone and IGF-1, drive the metabolic changes of acromegaly including insulin resistance, visceral fat redistribution, and the cardiovascular and metabolic consequences of growth hormone excess. Non-functioning microadenomas compress adjacent pituitary tissue, producing variable degrees of pituitary insufficiency across the axes of the cells displaced by the adenoma's growth and creating the metabolic consequences of the hormonal deficiencies their compression produces.
Functional hyperprolactinaemia, elevated prolactin driven by stress, medications, hypothyroidism, or dopamine pathway disruption without a structural pituitary lesion, is more common than prolactinoma in the Pakistani patient population and responds to treatment of its underlying drivers. Prolactinoma driven hyperprolactinaemia originates from autonomous prolactin secretion by a structurally abnormal pituitary cell population that produces prolactin independently of the normal regulatory signals, it does not resolve with stress reduction, medication withdrawal, or thyroid treatment, and it requires direct treatment with dopamine agonists or surgical intervention. The distinction between the two is made only by pituitary MRI, and in Pakistani clinical practice, where MRI is frequently deferred because prolactin elevation is attributed to functional causes without imaging, the prolactinoma that is actually responsible for the elevation is identified only when the clinical course fails to respond to functional management or when the lesion becomes large enough to produce compressive symptoms.
Dopamine is the primary inhibitory regulator of prolactin secretion from the pituitary, and simultaneously one of the most important neurotransmitters governing hypothalamic metabolic regulation, appetite control, reward signalling, and motivational drive. The dopamine pathway disruption produced by hyperprolactinaemia, in which elevated prolactin creates a feedback loop that further impairs hypothalamic dopaminergic tone, reduces dopamine availability across all of its hypothalamic functions simultaneously. Reduced hypothalamic dopamine impairs the satiety signalling that normal dopaminergic tone provides, increases food reward driven eating through its effects on the mesolimbic reward pathway, reduces the metabolic activation that dopamine mediated sympathetic nervous system tone normally produces, and drives the low mood and motivational flatness that Pakistani patients with prolactinoma frequently describe and that Pakistani physicians frequently attribute to depression rather than to dopaminergic disruption from a pituitary lesion.
Pituitary MRI is the only investigation that can determine whether elevated prolactin reflects a structural pituitary lesion or a functional hormonal disruption, and the distinction determines not only the treatment approach but the monitoring requirements, the treatment duration, and the follow up imaging schedule. A prolactinoma requires dopamine agonist treatment targeting both prolactin normalisation and adenoma shrinkage, with regular MRI surveillance for adenoma response and growth. Functional hyperprolactinaemia requires treatment of its underlying drivers, medication review, thyroid treatment, stress management, without the structural imaging follow up that a pituitary lesion demands. Starting a Pakistani patient on cabergoline for elevated prolactin without MRI treats the number without determining its origin, and in a patient with a prolactinoma, this management gap leaves the structural lesion unidentified, unmonitored, and potentially growing while the prolactin is controlled.
Pituitary microadenomas affect bone health through the hormonal deficiencies their direct and compressive effects produce. Prolactinoma driven GnRH suppression reduces oestrogen in women and testosterone in men, removing the bone density maintaining effects of sex hormones and accelerating the bone loss that sex hormone deficiency produces. Corticotroph adenomas produce cortisol excess that drives the bone resorption and impaired bone formation that characterise corticosteroid induced osteoporosis. Non-functioning adenomas that compress gonadotroph cells produce gonadotropin deficiency and secondary sex hormone deficiency with its consequent bone density loss. In Pakistani patients, where vitamin D deficiency is almost universal and where baseline bone density is frequently already compromised by nutritional and hormonal factors, the additional bone density loss from pituitary microadenoma related hormonal deficiency produces an osteoporotic burden that is never assessed because pituitary disease is never identified as the driver of the bone health deterioration it is producing.
Pituitary microadenomas, particularly prolactinomas, are a significant and frequently overlooked cause of fertility impairment in Pakistani women of reproductive age. The hyperprolactinaemia driven GnRH suppression that prolactinomas produce disrupts the LH and FSH pulsatility required for normal follicular development, ovulation, and corpus luteum function, producing the anovulatory infertility that brings many Pakistani women to fertility clinics where their prolactin is measured, found elevated, and treated with cabergoline without the MRI that would identify the structural pituitary origin of the elevation. In Pakistani women undergoing IVF for unexplained infertility or repeated implantation failure, the prevalence of unidentified pituitary microadenomas is substantially higher than clinical awareness in Pakistani reproductive medicine suggests, and the fertility outcomes of women with unidentified and inadequately treated pituitary lesions are consistently inferior to those whose structural pituitary pathology has been identified, imaged, and comprehensively managed.
THE CHROMOSOME protocol includes pituitary hormonal assessment, prolactin, IGF-1, morning cortisol, LH, FSH, and TSH as a coordinated pituitary axis evaluation, as a standard component of every comprehensive Pakistani obesity hormonal assessment, rather than ordering individual pituitary hormones only when a specific clinical suspicion triggers their measurement. Where pituitary axis hormonal abnormalities are identified, elevated prolactin, suppressed IGF-1, inappropriate cortisol, or disrupted gonadotropin patterns, pituitary MRI is requested as the definitive structural investigation that determines whether the hormonal disruption has a treatable pituitary structural origin. Where pituitary microadenomas are identified, treatment is designed around the complete hormonal picture, addressing not only the specific hormone the adenoma secretes in excess or the specific axis it compresses in insufficiency, but the full downstream metabolic and hormonal consequences that the pituitary disruption has produced across every dependent axis simultaneously. The pituitary is the conductor of the hormonal orchestra, and THE CHROMOSOME protocol is the only framework in Pakistani obesity medicine that consistently looks at the conductor rather than only at the musicians playing out of tune.